---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-24-000149"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2024-10-29T23:59:59+00:00"
generated_at: "2026-05-30T09:33:32.964439+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Exelixis Q3 revenue $539.5M, EPS $0.40; raises FY 2024 guidance

## Summary
- Q3 net product revenue $478.1M (cabozantinib franchise) vs $426.5M YoY, +12%.
- GAAP diluted EPS $0.40, non-GAAP diluted EPS $0.47; prior year $0.00 and $0.10.
- Raises 2024 total revenue and net product revenue guidance on strong commercial performance.
- Favorable U.S. District Court ruling on cabozantinib patent litigation received.
- New collaboration with Merck adds two phase 3 trials for zanzalintinib in renal cell carcinoma.

## SEC filing metadata
- accession: 0000939767-24-000149
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2024-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976724000149/0000939767-24-000149-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976724000149/exel-20241029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-24-000149
- JSON: https://secwatch.observer/filing/0000939767-24-000149.json
- Plain text: https://secwatch.observer/filing/0000939767-24-000149.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.